25 XP   0   0   10

Guard Therapeutics International AB
Buy, Hold or Sell?

Let's analyse Guard Therapeutics International AB together

PenkeI guess you are interested in Guard Therapeutics International AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Guard Therapeutics International AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Guard Therapeutics International AB

I send you an email if I find something interesting about Guard Therapeutics International AB.

Quick analysis of Guard Therapeutics International AB (30 sec.)










What can you expect buying and holding a share of Guard Therapeutics International AB? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr6.63
Expected worth in 1 year
kr-4.36
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
kr-11.00
Return On Investment
-37.1%

For what price can you sell your share?

Current Price per Share
kr29.60
Expected price per share
kr21.60 - kr40.40
How sure are you?
50%

1. Valuation of Guard Therapeutics International AB (5 min.)




Live pricePrice per Share (EOD)

kr29.60

Intrinsic Value Per Share

kr-115.99 - kr-52.99

Total Value Per Share

kr-109.36 - kr-46.36

2. Growth of Guard Therapeutics International AB (5 min.)




Is Guard Therapeutics International AB growing?

Current yearPrevious yearGrowGrow %
How rich?$6.1m$13.1m-$4.1m-46.0%

How much money is Guard Therapeutics International AB making?

Current yearPrevious yearGrowGrow %
Making money-$2.5m-$2.5m-$87.1k-3.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Guard Therapeutics International AB (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#722 / 1009

Most Revenue
#965 / 1009

Most Profit
#333 / 1009

Most Efficient
#409 / 1009

What can you expect buying and holding a share of Guard Therapeutics International AB? (5 min.)

Welcome investor! Guard Therapeutics International AB's management wants to use your money to grow the business. In return you get a share of Guard Therapeutics International AB.

What can you expect buying and holding a share of Guard Therapeutics International AB?

First you should know what it really means to hold a share of Guard Therapeutics International AB. And how you can make/lose money.

Speculation

The Price per Share of Guard Therapeutics International AB is kr29.60. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Guard Therapeutics International AB.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Guard Therapeutics International AB, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr6.63. Based on the TTM, the Book Value Change Per Share is kr-2.75 per quarter. Based on the YOY, the Book Value Change Per Share is kr4.28 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Guard Therapeutics International AB.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.16-0.5%-0.26-0.9%-0.10-0.3%-0.08-0.3%-0.08-0.3%
Usd Book Value Change Per Share-0.15-0.5%-0.25-0.9%0.391.3%0.030.1%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.15-0.5%-0.25-0.9%0.391.3%0.030.1%0.010.0%
Usd Price Per Share3.29-0.87-0.09-0.26-0.26-
Price to Earnings Ratio-5.27--1.36--2.99--3.36--2.70-
Price-to-Total Gains Ratio-21.96--5.66--11.67--6.04--7.28-
Price to Book Ratio5.40-1.40-2.01-4.05-2.35-
Price-to-Total Gains Ratio-21.96--5.66--11.67--6.04--7.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.72024
Number of shares367
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.250.03
Usd Total Gains Per Share-0.250.03
Gains per Quarter (367 shares)-92.7111.32
Gains per Year (367 shares)-370.8345.26
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-371-38104535
20-742-75209180
30-1113-11230136125
40-1483-14940181170
50-1854-18650226215
60-2225-22360272260
70-2596-26070317305
80-2967-29780362350
90-3338-33490407395
100-3708-37200453440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.047.01.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%6.014.00.030.0%10.030.00.025.0%11.034.03.022.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.048.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%6.014.00.030.0%10.030.00.025.0%11.034.03.022.9%

Fundamentals of Guard Therapeutics International AB

About Guard Therapeutics International AB

Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.

Fundamental data was last updated by Penke on 2024-04-22 02:24:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Guard Therapeutics International AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Guard Therapeutics International AB earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Guard Therapeutics International AB to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Guard Therapeutics International AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-2,251.2%+2,251.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY--288.3%+288.3%
5Y--449.1%+449.1%
10Y-2,251.2%-605.5%-1,645.7%
1.1.2. Return on Assets

Shows how efficient Guard Therapeutics International AB is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Guard Therapeutics International AB to the Biotechnology industry mean.
  • -20.1% Return on Assets means that Guard Therapeutics International AB generated kr-0.20 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Guard Therapeutics International AB:

  • The MRQ is -20.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -22.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.1%TTM-22.8%+2.7%
TTM-22.8%YOY-16.9%-5.8%
TTM-22.8%5Y-23.3%+0.5%
5Y-23.3%10Y-25.4%+2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.1%-13.3%-6.8%
TTM-22.8%-12.8%-10.0%
YOY-16.9%-11.7%-5.2%
5Y-23.3%-13.9%-9.4%
10Y-25.4%-15.7%-9.7%
1.1.3. Return on Equity

Shows how efficient Guard Therapeutics International AB is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Guard Therapeutics International AB to the Biotechnology industry mean.
  • -25.6% Return on Equity means Guard Therapeutics International AB generated kr-0.26 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Guard Therapeutics International AB:

  • The MRQ is -25.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -28.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.6%TTM-28.3%+2.7%
TTM-28.3%YOY-19.4%-8.9%
TTM-28.3%5Y-33.1%+4.8%
5Y-33.1%10Y-31.1%-2.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.6%-16.9%-8.7%
TTM-28.3%-16.1%-12.2%
YOY-19.4%-15.1%-4.3%
5Y-33.1%-19.3%-13.8%
10Y-31.1%-20.2%-10.9%

1.2. Operating Efficiency of Guard Therapeutics International AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Guard Therapeutics International AB is operating .

  • Measures how much profit Guard Therapeutics International AB makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Guard Therapeutics International AB to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Guard Therapeutics International AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-2,026.3%+2,026.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY--298.2%+298.2%
5Y--492.1%+492.1%
10Y-2,026.3%-632.4%-1,393.9%
1.2.2. Operating Ratio

Measures how efficient Guard Therapeutics International AB is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Guard Therapeutics International AB:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y19.783-19.783
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-3.890-3.890
5Y-5.739-5.739
10Y19.7837.876+11.907

1.3. Liquidity of Guard Therapeutics International AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Guard Therapeutics International AB is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.13 means the company has kr5.13 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Guard Therapeutics International AB:

  • The MRQ is 5.130. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.493. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.130TTM5.493-0.362
TTM5.493YOY10.053-4.560
TTM5.4935Y7.316-1.824
5Y7.31610Y4.846+2.470
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.1303.890+1.240
TTM5.4934.173+1.320
YOY10.0535.344+4.709
5Y7.3166.126+1.190
10Y4.8466.448-1.602
1.3.2. Quick Ratio

Measures if Guard Therapeutics International AB is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Guard Therapeutics International AB to the Biotechnology industry mean.
  • A Quick Ratio of 5.13 means the company can pay off kr5.13 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Guard Therapeutics International AB:

  • The MRQ is 5.130. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.493. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.130TTM5.493-0.362
TTM5.493YOY10.027-4.534
TTM5.4935Y7.249-1.756
5Y7.24910Y4.785+2.464
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.1303.514+1.616
TTM5.4933.998+1.495
YOY10.0275.380+4.647
5Y7.2496.105+1.144
10Y4.7856.404-1.619

1.4. Solvency of Guard Therapeutics International AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Guard Therapeutics International AB assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Guard Therapeutics International AB to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.22 means that Guard Therapeutics International AB assets are financed with 21.7% credit (debt) and the remaining percentage (100% - 21.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Guard Therapeutics International AB:

  • The MRQ is 0.217. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.197. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.217TTM0.197+0.020
TTM0.197YOY0.121+0.077
TTM0.1975Y0.213-0.016
5Y0.21310Y0.239-0.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2170.339-0.122
TTM0.1970.336-0.139
YOY0.1210.271-0.150
5Y0.2130.366-0.153
10Y0.2390.389-0.150
1.4.2. Debt to Equity Ratio

Measures if Guard Therapeutics International AB is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Guard Therapeutics International AB to the Biotechnology industry mean.
  • A Debt to Equity ratio of 27.7% means that company has kr0.28 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Guard Therapeutics International AB:

  • The MRQ is 0.277. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.246. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.277TTM0.246+0.031
TTM0.246YOY0.138+0.108
TTM0.2465Y0.298-0.052
5Y0.29810Y0.319-0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2770.388-0.111
TTM0.2460.402-0.156
YOY0.1380.335-0.197
5Y0.2980.426-0.128
10Y0.3190.461-0.142

2. Market Valuation of Guard Therapeutics International AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Guard Therapeutics International AB generates.

  • Above 15 is considered overpriced but always compare Guard Therapeutics International AB to the Biotechnology industry mean.
  • A PE ratio of -5.27 means the investor is paying kr-5.27 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Guard Therapeutics International AB:

  • The EOD is -4.355. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.267. Based on the earnings, the company is expensive. -2
  • The TTM is -1.357. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.355MRQ-5.267+0.912
MRQ-5.267TTM-1.357-3.910
TTM-1.357YOY-2.987+1.630
TTM-1.3575Y-3.360+2.003
5Y-3.36010Y-2.701-0.659
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.355-2.264-2.091
MRQ-5.267-2.629-2.638
TTM-1.357-2.680+1.323
YOY-2.987-4.145+1.158
5Y-3.360-6.257+2.897
10Y-2.701-6.254+3.553
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Guard Therapeutics International AB:

  • The EOD is -4.296. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.196. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.340. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.296MRQ-5.196+0.900
MRQ-5.196TTM-1.340-3.857
TTM-1.340YOY-3.253+1.914
TTM-1.3405Y-3.615+2.275
5Y-3.61510Y-2.561-1.054
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.296-2.973-1.323
MRQ-5.196-3.333-1.863
TTM-1.340-3.553+2.213
YOY-3.253-5.605+2.352
5Y-3.615-8.376+4.761
10Y-2.561-8.865+6.304
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Guard Therapeutics International AB is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.40 means the investor is paying kr5.40 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Guard Therapeutics International AB:

  • The EOD is 4.463. Based on the equity, the company is fair priced.
  • The MRQ is 5.398. Based on the equity, the company is overpriced. -1
  • The TTM is 1.395. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.463MRQ5.398-0.935
MRQ5.398TTM1.395+4.002
TTM1.395YOY2.010-0.614
TTM1.3955Y4.049-2.654
5Y4.04910Y2.350+1.700
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.4631.896+2.567
MRQ5.3982.115+3.283
TTM1.3952.093-0.698
YOY2.0102.884-0.874
5Y4.0493.542+0.507
10Y2.3503.916-1.566
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Guard Therapeutics International AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.630-2.749+69%4.279-138%0.335-586%0.103-1688%
Book Value Per Share--6.6329.774-32%4.694+41%3.078+115%3.232+105%
Current Ratio--5.1305.493-7%10.053-49%7.316-30%4.846+6%
Debt To Asset Ratio--0.2170.197+10%0.121+80%0.213+2%0.239-9%
Debt To Equity Ratio--0.2770.246+13%0.138+101%0.298-7%0.319-13%
Dividend Per Share----0%-0%-0%-0%
Eps---1.699-2.816+66%-1.058-38%-0.844-50%-0.839-51%
Free Cash Flow Per Share---1.722-2.883+67%-0.896-48%-0.810-53%-0.832-52%
Free Cash Flow To Equity Per Share---1.722-2.905+69%1.930-189%-0.133-92%0.455-478%
Gross Profit Margin--1.0651.038+3%1.039+3%1.046+2%1.0680%
Intrinsic Value_10Y_max---52.993--------
Intrinsic Value_10Y_min---115.992--------
Intrinsic Value_1Y_max---3.618--------
Intrinsic Value_1Y_min---6.285--------
Intrinsic Value_3Y_max---12.161--------
Intrinsic Value_3Y_min---23.620--------
Intrinsic Value_5Y_max---22.258--------
Intrinsic Value_5Y_min---46.011--------
Market Cap297823360.000-21%360205817.00095064653.426+279%265913512.878+35%207866678.873+73%123949932.467+191%
Net Profit Margin----0%-0%-0%-22.5120%
Operating Margin----0%-0%-0%-20.2630%
Operating Ratio----0%-0%-0%19.783-100%
Pb Ratio4.463-21%5.3981.395+287%2.010+169%4.049+33%2.350+130%
Pe Ratio-4.355+17%-5.267-1.357-74%-2.987-43%-3.360-36%-2.701-49%
Price Per Share29.600-21%35.8009.448+279%0.964+3616%2.830+1165%2.816+1171%
Price To Free Cash Flow Ratio-4.296+17%-5.196-1.340-74%-3.253-37%-3.615-30%-2.561-51%
Price To Total Gains Ratio-18.160+17%-21.964-5.655-74%-11.670-47%-6.038-73%-7.280-67%
Quick Ratio--5.1305.493-7%10.027-49%7.249-29%4.785+7%
Return On Assets---0.201-0.228+13%-0.169-16%-0.233+16%-0.254+26%
Return On Equity---0.256-0.283+11%-0.194-24%-0.331+29%-0.311+22%
Total Gains Per Share---1.630-2.749+69%4.279-138%0.335-586%0.103-1688%
Usd Book Value--6132762.7009037262.200-32%13196748.100-54%7513679.670-18%5595818.570+10%
Usd Book Value Change Per Share---0.150-0.253+69%0.393-138%0.031-586%0.009-1688%
Usd Book Value Per Share--0.6100.898-32%0.431+41%0.283+115%0.297+105%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.156-0.259+66%-0.097-38%-0.078-50%-0.077-51%
Usd Free Cash Flow---1592627.000-2666156.850+67%-2346643.525+47%-1810237.010+14%-1440355.593-10%
Usd Free Cash Flow Per Share---0.158-0.265+67%-0.082-48%-0.074-53%-0.076-52%
Usd Free Cash Flow To Equity Per Share---0.158-0.267+69%0.177-189%-0.012-92%0.042-478%
Usd Market Cap27369966.784-21%33102914.5828736441.650+279%24437451.833+35%19102947.788+73%11390998.794+191%
Usd Price Per Share2.720-21%3.2900.868+279%0.089+3616%0.260+1165%0.259+1171%
Usd Profit---1571122.400-2587513.425+65%-2500392.225+59%-1790781.780+14%-1454149.783-7%
Usd Revenue----0%-0%-0%32261.495-100%
Usd Total Gains Per Share---0.150-0.253+69%0.393-138%0.031-586%0.009-1688%
 EOD+3 -5MRQTTM+20 -10YOY+10 -205Y+13 -1710Y+15 -17

3.2. Fundamental Score

Let's check the fundamental score of Guard Therapeutics International AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.355
Price to Book Ratio (EOD)Between0-14.463
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than15.130
Current Ratio (MRQ)Greater than15.130
Debt to Asset Ratio (MRQ)Less than10.217
Debt to Equity Ratio (MRQ)Less than10.277
Return on Equity (MRQ)Greater than0.15-0.256
Return on Assets (MRQ)Greater than0.05-0.201
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Guard Therapeutics International AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.512
Ma 20Greater thanMa 5022.820
Ma 50Greater thanMa 10020.630
Ma 100Greater thanMa 20024.753
OpenGreater thanClose28.600
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets85,227
Total Liabilities18,494
Total Stockholder Equity66,733
 As reported
Total Liabilities 18,494
Total Stockholder Equity+ 66,733
Total Assets = 85,227

Assets

Total Assets85,227
Total Current Assets85,227
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 83,741
Net Receivables 1,486
Inventory -1
Other Current Assets 1
Total Current Assets  (as reported)85,227
Total Current Assets  (calculated)85,227
+/-0
Long-term Assets
Property Plant Equipment 2,023
Long-term Assets  (as reported)0
Long-term Assets  (calculated)2,023
+/- 2,023

Liabilities & Shareholders' Equity

Total Current Liabilities16,612
Long-term Liabilities1,882
Total Stockholder Equity66,733
Total Current Liabilities
Accounts payable 5,494
Other Current Liabilities 11,118
Total Current Liabilities  (as reported)16,612
Total Current Liabilities  (calculated)16,612
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)1,882
Long-term Liabilities  (calculated)0
+/- 1,882
Total Stockholder Equity
Common Stock10,062
Retained Earnings -676,039
Accumulated Other Comprehensive Income 0
Other Stockholders Equity 732,710
Total Stockholder Equity (as reported)66,733
Total Stockholder Equity (calculated)66,733
+/-0
Other
Capital Stock10,062
Cash and Short Term Investments 83,741
Common Stock Shares Outstanding 10,062
Liabilities and Stockholders Equity 85,227
Net Debt -83,741
Net Invested Capital 66,734
Net Working Capital 68,614



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312010-12-312009-06-30
> Total Assets 
2,638
3,956
7,777
0
0
0
47,824
46,945
45,581
43,582
47,170
47,585
61,205
60,106
57,966
59,325
52,467
42,334
51,691
42,583
72,500
60,343
42,469
38,841
68,427
52,674
43,647
44,109
63,877
48,294
27,276
53,245
65,131
51,365
63,714
57,564
47,131
28,770
91,222
81,627
67,580
37,036
190,437
172,727
152,857
123,273
202,605
167,492
130,228
104,781
85,227
85,227104,781130,228167,492202,605123,273152,857172,727190,43737,03667,58081,62791,22228,77047,13157,56463,71451,36565,13153,24527,27648,29463,87744,10943,64752,67468,42738,84142,46960,34372,50042,58351,69142,33452,46759,32557,96660,10661,20547,58547,17043,58245,58146,94547,8240007,7773,9562,638
   > Total Current Assets 
0
0
0
0
0
0
18,482
0
12,273
7,884
5,653
3,057
14,332
9,977
4,932
3,583
24,768
13,125
21,463
11,432
40,609
27,374
9,104
5,095
34,727
18,554
9,576
10,796
31,414
16,814
15,726
41,823
53,950
40,424
55,873
50,202
40,247
28,686
91,178
81,587
67,543
37,003
190,408
172,701
152,835
123,254
202,591
167,481
130,220
104,777
85,227
85,227104,777130,220167,481202,591123,254152,835172,701190,40837,00367,54381,58791,17828,68640,24750,20255,87340,42453,95041,82315,72616,81431,41410,7969,57618,55434,7275,0959,10427,37440,60911,43221,46313,12524,7683,5834,9329,97714,3323,0575,6537,88412,273018,482000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
17,291
0
11,880
7,101
4,618
2,562
13,045
9,133
4,136
2,546
22,988
11,702
19,387
10,069
39,248
26,542
7,009
1,912
33,205
17,981
7,612
4,330
27,339
14,496
13,959
39,252
52,333
39,447
53,971
46,777
37,122
25,991
90,042
80,419
66,939
35,919
188,605
171,260
151,334
122,173
201,008
165,387
128,253
103,195
83,741
83,741103,195128,253165,387201,008122,173151,334171,260188,60535,91966,93980,41990,04225,99137,12246,77753,97139,44752,33339,25213,95914,49627,3394,3307,61217,98133,2051,9127,00926,54239,24810,06919,38711,70222,9882,5464,1369,13313,0452,5624,6187,10111,880017,291000000
       Net Receivables 
69
10
44
0
0
0
1,134
244
312
707
839
318
1,156
702
705
955
1,706
1,423
1,882
1,325
1,339
810
1,303
1,228
1,516
568
925
2,324
1,255
821
0
0
0
977
1,377
1,451
987
1,352
709
938
421
771
931
711
812
1,082
1,582
2,094
1,967
1,582
1,486
1,4861,5821,9672,0941,5821,0828127119317714219387091,3529871,4511,3779770008211,2552,3249255681,5161,2281,3038101,3391,3251,8821,4231,7069557057021,1563188397073122441,134000441069
   > Long-term Assets 
0
0
0
0
0
0
29,342
0
33,308
35,698
41,517
44,528
46,873
50,129
53,034
55,742
27,699
29,209
30,228
31,151
31,891
32,969
33,365
33,746
33,700
34,119
34,071
33,313
32,463
31,480
11,550
11,422
11,181
10,941
7,841
7,362
6,884
84
44
40
37
33
29
26
22
18
15
11
7
4
0
04711151822262933374044846,8847,3627,84110,94111,18111,42211,55031,48032,46333,31334,07134,11933,70033,74633,36532,96931,89131,15130,22829,20927,69955,74253,03450,12946,87344,52841,51735,69833,308029,342000000
       Property Plant Equipment 
23
15
9
0
0
0
16
324
305
287
269
429
403
377
638
643
601
1,076
1,250
1,266
1,118
1,032
1,155
1,055
956
856
856
673
589
505
421
460
385
311
515
404
292
84
44
40
37
33
29
26
22
18
15
11
7
4
2,023
2,0234711151822262933374044842924045153113854604215055896738568569561,0551,1551,0321,1181,2661,2501,0766016436383774034292692873053241600091523
       Intangible Assets 
335
1,633
2,009
0
0
0
14,432
14,768
15,266
16,152
18,850
19,169
19,644
20,104
20,952
21,413
27,098
28,133
22,667
29,885
30,773
31,937
23,140
32,691
32,744
33,263
33,315
32,640
31,874
30,975
11,128
0
0
0
7,325
6,958
6,592
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000006,5926,9587,32500011,12830,97531,87432,64033,31533,26332,74432,69123,14031,93730,77329,88522,66728,13327,09821,41320,95220,10419,64419,16918,85016,15215,26614,76814,4320002,0091,633335
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-100
0
0
0
1
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000010001000-10000000000000000000000000000
> Total Liabilities 
299
872
5,658
0
0
0
17,245
17,485
17,781
17,162
21,754
23,449
5,852
6,493
5,713
10,019
8,876
5,672
9,004
6,633
8,388
10,589
12,132
24,196
6,535
9,116
11,682
21,724
9,998
11,007
30,215
17,145
16,480
10,748
11,090
14,589
12,876
13,986
11,536
15,213
12,698
16,363
14,660
15,737
16,716
19,369
25,244
29,671
24,563
21,648
18,494
18,49421,64824,56329,67125,24419,36916,71615,73714,66016,36312,69815,21311,53613,98612,87614,58911,09010,74816,48017,14530,21511,0079,99821,72411,6829,1166,53524,19612,13210,5898,3886,6339,0045,6728,87610,0195,7136,4935,85223,44921,75417,16217,78117,48517,2450005,658872299
   > Total Current Liabilities 
299
872
1,269
0
0
0
2,245
2,485
2,781
2,162
4,358
6,053
3,456
4,097
3,317
7,623
6,480
3,276
6,644
4,310
6,102
8,339
12,132
24,196
6,535
9,116
11,682
21,724
9,998
11,007
30,215
16,556
15,891
10,159
5,298
9,032
7,185
8,295
6,503
11,311
8,974
12,690
10,942
13,124
14,152
16,821
22,696
28,171
23,149
19,881
16,612
16,61219,88123,14928,17122,69616,82114,15213,12410,94212,6908,97411,3116,5038,2957,1859,0325,29810,15915,89116,55630,21511,0079,99821,72411,6829,1166,53524,19612,1328,3396,1024,3106,6443,2766,4807,6233,3174,0973,4566,0534,3582,1622,7812,4852,2450001,269872299
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,500
0
0
584
387
283
0
0
0
0
0
0
0
0
0
0
0
0
0
176
148
104
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001041481760000000000000283387584002,500000000000000000
       Accounts payable 
273
330
413
0
0
0
559
618
761
621
3,481
3,822
2,010
1,279
1,318
3,262
4,516
1,692
3,480
2,878
4,237
6,218
9,517
14,460
4,993
8,074
7,841
17,550
8,969
9,085
13,802
12,880
13,501
8,376
2,519
6,212
4,594
6,400
2,978
8,195
3,267
9,323
6,289
9,020
6,664
9,561
11,220
10,761
9,698
8,850
5,494
5,4948,8509,69810,76111,2209,5616,6649,0206,2899,3233,2678,1952,9786,4004,5946,2122,5198,37613,50112,88013,8029,0858,96917,5507,8418,0744,99314,4609,5176,2184,2372,8783,4801,6924,5163,2621,3181,2792,0103,8223,481621761618559000413330273
       Other Current Liabilities 
26
541
857
0
0
0
1,686
1,867
2,020
1,541
877
2,231
1,446
2,818
1,999
366
1,964
1,584
2,580
-1
1,582
2,121
2,615
9,736
1,542
1,042
3,841
4,174
1,029
1,922
16,413
3,676
2,390
1,783
178
209
163
1,895
3,525
3,116
5,707
3,367
4,653
4,104
7,488
7,260
11,476
17,410
13,451
11,031
11,118
11,11811,03113,45117,41011,4767,2607,4884,1044,6533,3675,7073,1163,5251,8951632091781,7832,3903,67616,4131,9221,0294,1743,8411,0421,5429,7362,6152,1211,582-12,5801,5841,9643661,9992,8181,4462,2318771,5412,0201,8671,68600085754126
   > Long-term Liabilities 
0
0
0
0
0
0
15,000
0
15,000
15,000
17,396
17,396
2,396
2,396
2,396
2,396
2,396
2,396
2,360
2,323
2,286
2,250
9,517
14,460
4,993
8,074
7,841
17,550
8,969
9,085
13,802
589
589
589
5,792
5,557
5,691
5,691
5,033
3,902
3,724
3,673
3,718
2,613
2,564
2,548
2,548
1,500
1,414
1,767
1,882
1,8821,7671,4141,5002,5482,5482,5642,6133,7183,6733,7243,9025,0335,6915,6915,5575,79258958958913,8029,0858,96917,5507,8418,0744,99314,4609,5172,2502,2862,3232,3602,3962,3962,3962,3962,3962,39617,39617,39615,00015,000015,000000000
       Other Liabilities 
0
0
4,389
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
590
590
5,777
5,557
5,691
5,691
5,033
3,903
3,724
3,673
3,719
2,614
2,565
2,548
2,549
0
1,414
0
0
001,41402,5492,5482,5652,6143,7193,6733,7243,9035,0335,6915,6915,5575,777590590000000000000000000000000000004,38900
> Total Stockholder Equity
2,339
3,084
2,119
2,119
0
0
30,579
29,460
27,800
26,420
25,416
24,136
55,353
53,613
52,253
49,306
43,591
36,662
42,687
35,950
64,112
49,754
30,337
14,645
61,892
43,558
31,965
22,385
53,879
37,287
-2,939
36,100
48,651
40,617
52,624
42,975
34,255
14,784
79,686
66,414
54,882
20,673
175,777
156,990
136,141
103,904
177,361
137,821
105,665
83,133
66,733
66,73383,133105,665137,821177,361103,904136,141156,990175,77720,67354,88266,41479,68614,78434,25542,97552,62440,61748,65136,100-2,93937,28753,87922,38531,96543,55861,89214,64530,33749,75464,11235,95042,68736,66243,59149,30652,25353,61355,35324,13625,41626,42027,80029,46030,579002,1192,1193,0842,339
   Common Stock
137
200
200
0
0
0
307
307
307
307
615
615
1,159
1,159
1,159
1,159
1,404
1,404
1,512
1,512
2,185
2,185
2,185
2,185
6,451
6,451
6,638
6,638
16,597
16,597
16,597
41,494
51,867
51,867
52,356
3,082
3,082
3,082
4,260
4,260
4,260
4,260
6,862
6,862
6,862
6,862
10,062
10,062
10,062
10,062
10,062
10,06210,06210,06210,06210,0626,8626,8626,8626,8624,2604,2604,2604,2603,0823,0823,08252,35651,86751,86741,49416,59716,59716,5976,6386,6386,4516,4512,1852,1852,1852,1851,5121,5121,4041,4041,1591,1591,1591,159615615307307307307000200200137
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
45,424
94,698
49,542
369,658
443,273
443,273
443,324
0
618,792
618,984
619,135
619,267
730,015
730,395
731,204
0
0
00731,204730,395730,015619,267619,135618,984618,7920443,324443,273443,273369,65849,54294,69845,4240000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
32,358
0
30,272
30,272
29,965
24,801
57,258
57,258
57,257
51,094
97,580
97,580
114,293
114,293
150,991
150,991
150,991
150,991
212,574
212,574
215,809
221,335
257,654
257,654
257,654
285,740
298,947
298,947
45,424
94,698
49,542
369,658
443,273
443,273
443,324
443,577
618,792
618,984
619,135
619,267
730,015
730,395
731,204
732,014
732,710
732,710732,014731,204730,395730,015619,267619,135618,984618,792443,577443,324443,273443,273369,65849,54294,69845,424298,947298,947285,740257,654257,654257,654221,335215,809212,574212,574150,991150,991150,991150,991114,293114,29397,58097,58051,09457,25757,25857,25824,80129,96530,27230,272032,358000000



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-15
Gross Profit-15-15
 
Operating Income (+$)
Gross Profit-15
Operating Expense-114,907
Operating Income-114,922-114,922
 
Operating Expense (+$)
Research Development105,773
Selling General Administrative5
Selling And Marketing Expenses4
Operating Expense114,907105,782
 
Net Interest Income (+$)
Interest Income875
Interest Expense-447
Other Finance Cost-442
Net Interest Income870
 
Pretax Income (+$)
Operating Income-114,922
Net Interest Income870
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-113,323-116,521
EBIT - interestExpense = -115,369
1,484
-112,876
Interest Expense447
Earnings Before Interest and Taxes (EBIT)-114,922-112,876
Earnings Before Interest and Taxes (EBITDA)-114,907
 
After tax Income (+$)
Income Before Tax-113,323
Tax Provision-0
Net Income From Continuing Ops-136,718-113,323
Net Income-113,323
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses114,922
Total Other Income/Expenses Net1,599-870
 

Technical Analysis of Guard Therapeutics International AB
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Guard Therapeutics International AB. The general trend of Guard Therapeutics International AB is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Guard Therapeutics International AB's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Guard Therapeutics International AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 33.60 < 34.80 < 40.40.

The bearish price targets are: 21.80 > 21.80 > 21.60.

Tweet this
Guard Therapeutics International AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Guard Therapeutics International AB. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Guard Therapeutics International AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Guard Therapeutics International AB. The current macd is 2.81307572.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Guard Therapeutics International AB price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Guard Therapeutics International AB. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Guard Therapeutics International AB price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Guard Therapeutics International AB Daily Moving Average Convergence/Divergence (MACD) ChartGuard Therapeutics International AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Guard Therapeutics International AB. The current adx is 45.26.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Guard Therapeutics International AB shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Guard Therapeutics International AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Guard Therapeutics International AB. The current sar is 22.47.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Guard Therapeutics International AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Guard Therapeutics International AB. The current rsi is 69.51. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Guard Therapeutics International AB Daily Relative Strength Index (RSI) ChartGuard Therapeutics International AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Guard Therapeutics International AB. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Guard Therapeutics International AB price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Guard Therapeutics International AB Daily Stochastic Oscillator ChartGuard Therapeutics International AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Guard Therapeutics International AB. The current cci is 87.99.

Guard Therapeutics International AB Daily Commodity Channel Index (CCI) ChartGuard Therapeutics International AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Guard Therapeutics International AB. The current cmo is 40.97.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Guard Therapeutics International AB Daily Chande Momentum Oscillator (CMO) ChartGuard Therapeutics International AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Guard Therapeutics International AB. The current willr is -23.80952381.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Guard Therapeutics International AB is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Guard Therapeutics International AB Daily Williams %R ChartGuard Therapeutics International AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Guard Therapeutics International AB.

Guard Therapeutics International AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Guard Therapeutics International AB. The current atr is 2.94290103.

Guard Therapeutics International AB Daily Average True Range (ATR) ChartGuard Therapeutics International AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Guard Therapeutics International AB. The current obv is -1,029,049.

Guard Therapeutics International AB Daily On-Balance Volume (OBV) ChartGuard Therapeutics International AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Guard Therapeutics International AB. The current mfi is 76.36.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Guard Therapeutics International AB Daily Money Flow Index (MFI) ChartGuard Therapeutics International AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Guard Therapeutics International AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Guard Therapeutics International AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Guard Therapeutics International AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.512
Ma 20Greater thanMa 5022.820
Ma 50Greater thanMa 10020.630
Ma 100Greater thanMa 20024.753
OpenGreater thanClose28.600
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Guard Therapeutics International AB with someone you think should read this too:
  • Are you bullish or bearish on Guard Therapeutics International AB? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Guard Therapeutics International AB? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Guard Therapeutics International AB

I send you an email if I find something interesting about Guard Therapeutics International AB.


Comments

How you think about this?

Leave a comment

Stay informed about Guard Therapeutics International AB.

Receive notifications about Guard Therapeutics International AB in your mailbox!